The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Durability of immune checkpoint inhibitor (ICI) response following treatment discontinuation in advanced merkel cell carcinoma (MCC).
 
Tanya Ramadoss
No Relationships to Disclose
 
Matthew Nichols
No Relationships to Disclose
 
Christian Palacios
No Relationships to Disclose
 
Zeynep Eroglu
Consulting or Advisory Role - Incyte; Pfizer; Regeneron; Sun Pharma
Research Funding - Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst)
 
Joseph Markowitz
Stock and Other Ownership Interests - Aflac; Amdocs; Consolidated Edison; CVS; Intel
Consulting or Advisory Role - Newlink Genetics
Research Funding - Idera (Inst); Merck (Inst); Morphogenesis (Inst)
Patents, Royalties, Other Intellectual Property - Patent on development of Inhibitors for S100B (Inst); Pending patent on flow cytometry analysis system (Inst); Pending patent on the role of nitric oxide in melanoma. (Inst)
Other Relationship - Springer
 
Lilit Karapetyan
No Relationships to Disclose
 
Ahmad A. Tarhini
Consulting or Advisory Role - AstraZeneca; Bayer; BioNTech; Bristol-Myers Squibb; Clinigen Group; ConcertAI; Eisai; Genentech/Roche; Instil Bio; Merck; Nested; Novartis; Partner Therapeutics; Sanofi/Regeneron
Research Funding - Acrotech Biopharma (Inst); Agenus (Inst); Agenus (Inst); Bristol-Myers Squibb (Inst); Clinigen Group (Inst); Genentech/Roche (Inst); InflaRx (Inst); Merck (Inst); OncoSec (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst); Scholar Rock (Inst)
 
Evan John Wuthrick
No Relationships to Disclose
 
Vernon K. Sondak
Consulting or Advisory Role - Alkermes; Bristol-Myers Squibb; Genesis Drug Discovery & Development; Iovance Biotherapeutics; Merck/Schering Plough; Novartis; Regeneron; Sun Pharma; Ultimovacs
Research Funding - Neogene Therapeutics (Inst); Skyline Diagnostics (Inst); Turnstone Bio (Inst)
 
Nikhil I. Khushalani
Stock and Other Ownership Interests - Amarin Corporation; Asensus Surgical; Bellicum Pharmaceuticals
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Castle Biosciences; Genzyme; Immunocore; Incyte; Instil Bio; Iovance Biotherapeutics; Jounce Therapeutics; Merck; NCCN/Pfizer; Nektar; Novartis; Regeneron; Replimune
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); Merck (Inst); Modulation Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Castle Biosciences; Regeneron
Other Relationship - Bristol-Myers Squibb/Celgene; Nektar; Regeneron; Replimune; T-knife Therapeutics
 
Kenneth Yee Tsai
Stock and Other Ownership Interests - Dimerix; NFlection Therapeutics
Consulting or Advisory Role - EMD Serono; NFLection Therapeutics; Sun Pharma; Verrica Pharmaceuticals; Voiant Clinical
Research Funding - FORMA Therapeutics
Patents, Royalties, Other Intellectual Property - NFlection Therapeutics and Moffitt Cancer Center, John Kincaid, Kavita Sarin, Kenneth Y. Tsai, ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS, 046776-523P01US, 11/20/2019; UCSB, Samir Mitragotri, Byeong Hee Hwang, Nishit Doshi, Kenneth Tsai, Russell M. Lebovitz. COMPOSITIONS FOR SOLUBILIZING CELLS AND/OR TISSUE, United States, 13/432,978, 3/28/2012.
 
Andrew Scott Brohl
Consulting or Advisory Role - Bayer; Deciphera
Expert Testimony - GlaxoSmithKline (I)